Applying the CAMP trial asthma remission prediction model to the Dutch asthma remission studies - 04/05/19
Doi : 10.1016/j.jaci.2019.01.040
Orestes A. Carpaij, MD a, b, Judith M. Vonk, PhD a, c, Martijn C. Nawijn, PhD a, d, Huib A.M. Kerstjens, MD, PhD a, b, Gerard H. Koppelman, MD, PhD a, e, Maarten van den Berge, MD, PhD a, b 
a Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
b Department of Pulmonology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
c Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
d Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
e Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: M. C. Nawijn reports grant support from GlaxoSmithKline and Health Holland; unrestricted research grant on this topic; and unrestricted research grants sponsored by GlaxoSmithKline, TETRI Foundation, and Lung Foundation, SAB. H. A. M. Kerstjens received fees per patient for recruitment in trials from GlaxoSmithKline, NOVARTIS, and FLUIDDA and grants for investigator-initiated studies from GlaxoSmithKline, NOVARTIS, and Boerhinger. In addition, his institution has through his work received consultancy fees from Novartis, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. G. H. Koppelman received grant support from the Lung Foundation of the Netherlands, TETRI Foundation, TEVA the Netherlands, UBBO EMMIUS Foundation, Vertex, and GlaxoSmithKline (money to institution). M. van den Berge had grants paid to university from GlaxoSmithKline, Chiesi, Teva, AstraZeneca, and Genentech. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2019
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 5
P. 1973-1975 - mai 2019 Retour au numéro
Article précédent
- Reply
- Niki Mitselou, Erik Melén, Jonas F. Ludvigsson
- Reply
- Alberta L. Wang, Kelan G. Tantisira
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?